Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Katy Darribat"'
Autor:
Diethilde Theil, Reginald Valdez, Katy Darribat, Arno Doelemeyer, Rajeev Sivasankaran, Andreas Hartmann
Publikováno v:
Biology Open, Vol 10, Iss 10 (2021)
Branaplam is a therapeutic agent currently in clinical development for the treatment of infants with type 1 spinal muscular atrophy (SMA). Since preclinical studies showed that branaplam had cell-cycle arrest effects, we sought to determine whether b
Externí odkaz:
https://doaj.org/article/680c682b3d6644c1bab65daad281735d
Autor:
Diethilde Theil, Paul Smith, Catherine Huck, Yoann Gilbart, Algirdas Kakarieka, David Leppert, Celine Rauld, Cindy Schmid, Reto Baumgartner, Nathalie Stuber, Francisco Cordoba, Valerie Dubost, Katy Darribat, Magali Jivkov, Wilfried Frieauff, Rainer Kneuer, Markus Stoeckli, Stefan Reinker, Keith Mansfield, José M. Carballido, Philippe Couttet, Gisbert Weckbecker
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Ofatumumab is the first, fully human, anti-CD20 monoclonal antibody in Phase 3 development for multiple sclerosis (MS). The study focused on changes in lymphocyte subsets in blood and lymphoid tissues and on potential novel biomarkers as a result of
Externí odkaz:
https://doaj.org/article/ba3d555b05114fb2a5dab3fbd7970781
Autor:
Kirsten D. Mertz, Fernanda do Valle Duraes, Rachel Cuttat, Katy Darribat, Ulrike Naumann, Guglielmo Roma, Armelle Lafont, Swann Gaulis, Sabina Pfister, Martin Beibel, Jianping Li, Max Warncke, Kea Martin, Grazyna Wieczorek, Annick Waldt
Publikováno v:
JCI Insight. 5
Acute kidney injury (AKI) and chronic kidney diseases are associated with high mortality and morbidity. Although the underlying mechanisms determining the transition from acute to chronic injury are not completely understood, immune-mediated processe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8d0328a29ccc3ffec499ede36579cd5
https://doi.org/10.1172/jci.insight.130651
https://doi.org/10.1172/jci.insight.130651
Autor:
Catherine Huck, Francisco Cordoba, Markus Stoeckli, Rainer Kneuer, Keith Mansfield, Katy Darribat, Philippe Couttet, José M. Carballido, Yoann Gilbart, Paul Smith, Cindy Schmid, Celine Rauld, Wilfried Frieauff, Stefan Reinker, Reto Baumgartner, Valerie Dubost, Algirdas Kakarieka, Nathalie Stuber, Magali Jivkov, Gisbert Weckbecker, Diethilde Theil, David Leppert
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology, Vol 10 (2019)
Ofatumumab is the first, fully human, anti-CD20 monoclonal antibody in Phase 3 development for multiple sclerosis (MS). The study focused on changes in lymphocyte subsets in blood and lymphoid tissues and on potential novel biomarkers as a result of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9254dce9b979fb111b1dbbfd5133eb
https://pubmed.ncbi.nlm.nih.gov/31281311
https://pubmed.ncbi.nlm.nih.gov/31281311
Autor:
Steven Busch, Katy Darribat, Olivier Grenet, Philippe Couttet, Serafino Pantano, Valerie Dubost, Pierre Moulin
Publikováno v:
Journal of molecular histology. 44(6)
Dipeptidyl peptidase IV (DPP4) is a peptidase whose inhibition is beneficial in Type II diabetes treatment. Several evidences suggest potential implication of DPP4 in skin disorders such as psoriasis, keloids and fibrotic skin diseases where its inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bff1390a186fa2a838d2cf92562844b6
https://pubmed.ncbi.nlm.nih.gov/23880984
https://pubmed.ncbi.nlm.nih.gov/23880984